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Xanthohumol is the principal prenylated ﬂavonoid in the hop plant (Humulus lupulus L.). Xanthohumol was found to be a very
potent cancer chemopreventive agent through regulation of diverse mechanisms. However, no data are available concerning the
eﬀects of xanthohumol on platelet activation. The aim of this paper was to examine the antiplatelet eﬀect of xanthohumol in
washed human platelets. In the present paper, xanthohumol exhibited more-potent activity in inhibiting platelet aggregation
stimulated by collagen. Xanthohumol inhibited platelet activation accompanied by relative [Ca2+]i mobilization, thromboxane
A2 formation, hydroxyl radical (OH•) formation, and phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated
protein kinase (MAPK), and Akt phosphorylation. Neither SQ22536, an inhibitor of adenylate cyclase, nor ODQ, an inhibitor
of guanylate cyclase, reversed the xanthohumol-mediated inhibitory eﬀect on platelet aggregation. Furthermore, xanthohumol
did not signiﬁcantly increase nitrate formation in platelets. This study demonstrates for the ﬁrst time that xanthohumol possesses
potent antiplatelet activity which may initially inhibit the PI3-kinase/Akt, p38 MAPK, and PLCγ2-PKC cascades, followed by
inhibition of the thromboxane A2 formation, thereby leading to inhibition of [Ca2+]i and ﬁnally inhibition of platelet aggregation.
Therefore,thisnovelroleofxanthohumolmayrepresentahightherapeuticpotentialfortreatmentorpreventionofcardiovascular
diseases.
1.Introduction
Dietary factors play key roles in developing and preventing
various human diseases, including cardiovascular diseases
(CVDs). Epidemiological studies showed aninverse relation-
ship between diets rich in fruits, vegetables, and spices, and
the risk of all causes of death from cancer and CVD [1].
Hops (Humulus lupulus L.) have long been used in the brew-
ing industry as a preservative and ﬂavoring agent to add bit-
terness and aroma to beer [2]. In traditional Chinese medi-
cine, hops are used to treat insomnia, restlessness, dyspepsia,
and lack of an appetite. Alcoholic extracts of hops are clini-
call used in China to treat leprosy, pulmonary tuberculo-
sis, acute bacterial dysentery, silicosis, and asbestosis with
positive outcomes [2]. Xanthohumol is the principal preny-
lated ﬂavonoid in the hop plant. Recently, xanthohumol has
attracted considerable interest because of its biological activ-
ities, including anticancer, antiangiogenesis, anti-inﬂam-
mation,andantioxidation[3].Xanthohumol(1∼50μM)was
shown to suppress tumor growth by inhibiting cell prolif-
eration and inducing apoptosis in various carcinoma cells
[4–6]. It also exhibited antiangiogenic activity through in-
hibiting nuclear factor (NF)-κB and Akt activation in vas-
cular endothelial cells [7]. Furthermore, xanthohumol was
reported to regulate the function and survival of immune
cells by inhibiting the production of two important cytok-
ines, monocyte chemoattractant protein(MCP)-1, and
tumor necrosis factor (TNF)-α, in lipopolysaccharide-stim-2 Evidence-Based Complementary and Alternative Medicine
ulated macrophages [8]. Xanthohumol also prevented hep-
atic inﬂammation and ﬁbrosis in vivo and promoted den-
dritic cell apoptosis [3, 9]. Furthermore, xanthohumol was
able to scavenge reactive oxygen species (ROS) in tissue-plas-
minogen activator-(TPA-) stimulated diﬀerentiated HL-60
cells [4].
Intravascular thrombosis is one of the generators of a
widevarietyofCVDs.Initiationofanintraluminalthrombo-
sis is believed to involve platelet adherence and aggregation.
Thus, platelet aggregation may play a crucial role in the athe-
rothrombotic process [10]. Blood platelet activation and
aggregation are common denominators in atherothrombotic
events. Platelets are exclusively viewed as mediators of
thrombosis and hemostasis. Therefore, investigation of the
use of antiplatelet agents that inhibit atherothrombotic
events (myocardial infarction, ischemic stroke, and vascular
death) is warranted.
Olas et al. [11] reported that the extract of hops signif-
icantly reduced oxidative stress in peroxynitrite-stimulated
platelets. However, the detailed mechanisms underlying xan-
thohumol’s signaling pathways in regulating platelet func-
tions remain obscure. In the present study, we therefore for
the ﬁrst time examined in detail cellular signaling events as-
sociated with xanthohumol-mediated platelet function.
2.MaterialsandMethods
2.1. Materials. Xanthohumol, collagen (type I), luciferin-
luciferase, arachidonic acid (AA), phorbol-12,13-dibutyrate
(PDBu), 5,5-dimethyl-1 pyrroline N-oxide (DMPO),
SQ22536, ODQ, and thrombin were purchased from Sigma
(St. Louis, MO, USA). Fura 2-AM and ﬂuorescein isothi-
ocyanate (FITC) were from Molecular Probe (Eugene, OR,
USA). The thromboxane B2 enzyme immunoassay (EIA) kit
was from Cayman (Ann Arbor, MI, USA). The anti-
phospho-p38 mitogen-activated protein kinase (MAPK)
Ser182 monoclonal antibody (mAb) was from Santa Cruz
(Santa Cruz, CA). The anti-p38 MAPK and anti-phospho-
c-Jun N-terminal kinase (JNK) (Thr183/Tyr185) mAbs, and
antiphospholipase Cγ2( P L C γ2), anti-phospho (Tyr759)
PLCγ2, and anti-phospho-p44/p42 extracellular signal-
regulated kinase (ERK) (Thr202/Tyr204) polyclonal anti-
bodies (pAbs) were from Cell Signaling (Beverly, MA, USA).
Anti-phospho-Akt (Ser473) and anti-Akt mAbs were from
Biovision (Mountain View, CA, USA). The anti-α-tubulin
mAb was from NeoMarkers (Fremont, CA, USA). The
Hybond-Ppolyvinylidenediﬂuoride(PVDF)membrane,en-
hancedchemiluminescence(ECL)westernblottingdetection
reagent, and analysis system, horseradish peroxidase-(HRP-
)conjugated donkey anti-rabbit immunoglobulin G (IgG),
and sheep anti-mouse IgG were from Amersham (Bucking-
hamshire, UK). Xanthohumol was dissolved in 0.5% dim-
ethyl sulfoxide (DMSO) and stored at 4◦C until used.
2.2. Platelet Aggregation. Human platelet suspensions were
prepared as previously described [10]. This study was ap-
proved by the Institutional Review Board of Taipei Medical
University and conformed to the principles outlined in the
Helsinki Declaration, and all human volunteers provided
informed consent. In brief, blood was collected from healthy
human volunteers who had taken no medication during the
preceding 2 weeks, and was mixed with acid-citrate-dextrose
solution. After centrifugation, the supernatant (platelet-rich
plasma; PRP) was supplemented with 0.5μM prostaglandin
E1 (PGE1) and 6.4IU/mL heparin. Washed platelets were
ﬁnally suspended in Tyrode’s solution containing 3.5mg/mL
bovine serum albumin (BSA). The ﬁnal concentration of
Ca2+ in Tyrode’s solution was 1mM.
A turbidimetric method was used to measure platelet ag-
gregation[10],withaLumi-Aggregometer(Payton,Scarbor-
ough,ON,Canada).Plateletsuspensions(3.6×108 cells/mL)
were preincubated with various concentrations of xan-
thohumol or an isovolumetric solvent control (ﬁnal concen-
tration, 0.5% DMSO) for 3min before the addition of ago-
nists. The reaction was allowed to proceed for 6min, and
the extent of aggregation was expressed in light-transmis-
sion units. When measuring ATP release, 20μLo fal u c i f e r -
in/luciferase mixture was added 1min before the addition of
agonists, and ATP release was compared to that of the con-
trol.
2.3. Flow Cytometric Analysis. Fluorescence-conjugated tri-
ﬂavin, an αIIbβ3 disintegrin, was prepared as previously de-
scribed [12]. Platelet suspensions (3.6 × 108 cells/mL) were
preincubated with 1.5 and 3μM xanthohumol or a solvent
control for 3min, followed by the addition of 2μLo f
2μg/mL FITC-triﬂavin. Suspensions were then assayed for
ﬂuorescein-labeled platelets using a ﬂow cytometer (Beck-
man Coulter, Miami, FL, USA). Data were collected from
50,000 platelets per experimental group, and platelets were
identiﬁed on the basis of their characteristic forward and
orthogonal light-scattering proﬁles. All experiments were
repeated at least four times to ensure reproducibility.
2.4. Measurement of Relative [Ca2+]i Mobilization by Fura 2-
AM Fluorescence. Citrated whole blood was centrifuged at
120 × g for 10min. The supernatant was incubated with
5μMFura2-AMfor1h.Humanplateletswerethenprepared
as described above. Finally, the external Ca2+ concentration
of the platelet suspensions was adjusted to 1mM. Relative
[Ca2+]i mobilization was measured using a ﬂuorescence
spectrophotometer(CAF110,Jasco,Tokyo,Japan)withexci-
tation wavelengths of 340 and 380nm, and an emission
wavelength of 500nm [10].
2.5. Measurement of Thromboxane B2 Formation. Platelet
suspensions(3.6×108 cells/mL)werepreincubatedwithxan-
thohumol (1.5∼10μM) or a solvent control for 3min before
the addition of agonists. Six minutes after the addition of
agonists, 2mM EDTA and 50μM indomethacin were added
to the suspensions. Thromboxane B2 levels of the superna-
tants were measured using an EIA kit.
2.6. Immunoblotting. Washed platelets (1.2 × 109 cells/mL)
were preincubated with 1.5 and 3μM xanthohumol or aEvidence-Based Complementary and Alternative Medicine 3
solvent control for 3min, followed by the addition of ago-
nists to trigger platelet activation. The reaction was stopped,
andplateletswereimmediatelyresuspendedin200μLoflysis
buﬀer.Samplescontaining80μgofproteinwereseparatedby
a 12% sodium dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE); proteins were electrotransferred by
semidry transfer (Bio-Rad, Hercules, CA, USA). Blots were
blocked with TBST (10mM Tris-base, 100mM NaCl, and
0.01% Tween 20) containing 5% BSA for 1h and then
probed with various primary antibodies. Membranes were
incubated with HRP-linked anti-mouse IgG or anti-rabbit
IgG (diluted 1:3000 in TBST) for 1h. Immunoreactive
bandsweredetectedbyanECLsystem.Thebargraphdepicts
the ratios of semiquantitative results obtained by scanning
reactive bands and quantifying the optical density using vid-
eodensitometry (Bio-proﬁl; Biolight Windows Application
V2000.01; Vilber Lourmat, France).
2.7. Estimation of Nitrate Formation. In brief, platelet sus-
pensions(109 cells/mL)werepreincubatedwith1.5and3μM
xanthohumol or a solvent control for 3min, followed by
centrifugation. The amount of nitrate in the platelet suspen-
sions (10μL) was measured by adding a reducing agent to
the purge vessel to convert nitrate to NO which was stripped
from the suspensions by purging with helium gas [12]. The
NO was then drawn into a Sievers Nitric Oxide Analyzer
(Sievers 280 NOA, Boulder, CO, USA). Nitrate concentra-
tions were calculated by comparison to standard solutions of
sodium nitrate.
2.8. Measurement of Hydroxyl Radicals by Electron Spin Reso-
nance (ESR) Spectrometry. The ESR method used a Bruker
EMXESRspectrometerasdescribedpreviously[13].Inbrief,
platelet suspensions (3.6 × 108 cells/mL) were preincubated
with 1.5 and 3μM xanthohumol or a solvent control for
3min before the addition of 1μg/mL collagen. The reaction
was allowed to proceed for 5min, followed by the addition
of 100μM DMPO for the ESR study. The rate of free radical-
scavenging activity was deﬁned by the following equation:
inhibition rate = 1–

signal height (xanthohumol)
signal height (control)

,
(1)
(see [13]).
2.9. Data Analysis. Experimental results are expressed as
the means ± S . E . M .a n da r ea c c o m p a n i e db yt h en u m b e r
of observations. Experiments were assessed by an analysis
of variance (ANOVA). If this analysis indicated signiﬁcant
diﬀerences among group means, then each group was
compared using the Newman-Keuls method. P<0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Eﬀects of Xanthohumol on Platelet Aggregation and Rela-
tive [Ca2+]i Mobilization in Washed Human Platelets. Xan-
thohumol (1.5 and 3μM) exhibited very potent activity in
inhibiting platelet aggregation and the ATP-release reaction
stimulated by 1μg/mL collagen (Figure 1(a)); it also signif-
icantly inhibited platelet aggregation stimulated by 60μM
AA at higher concentrations (3 and 10μM) (Figure 1(a)).
However, it did not signiﬁcantly inhibit platelet aggregation
stimulated by 0.05U/mL thrombin or 1μM U46619, a
prostaglandin endoperoxide, at the same concentrations (3
and 10μM) (Figure 1(a)). The 50% inhibitory concentration
(IC50)valueofxanthohumolforplateletaggregationinduced
by collagen was approximately 1.5μM( Figure 1(b)). The
solvent control (0.5% DMSO) did not signiﬁcantly aﬀect
platelet aggregation stimulated by agonists (Figure 1(a)). In
subsequent experiments, we used collagen as an agonist
to explore the inhibitory mechanisms of xanthohumol in
platelet activation.
As shown in Figure 1(c),1 μg/mL collagen evoked a
marked increase in relative Ca2+ mobilization, and this in-
crease was markedly inhibited in the presence of xanthohu-
mol (1.5μM, 50.8 ±9.5% and 3μM, 66.5 ±9.6%; n = 3).
3.2. Inﬂuence of Xanthohumol on αIIbβ3 Integrin Confor-
mational Changes, Thromboxane B2 Formation, and PLCγ2
Phosphorylation. Triﬂavin is an αIIbβ3 disintegrin which in-
hibits platelet aggregation by directly interfering with ﬁb-
rinogen binding to the αIIbβ3 integrin [12]. Therefore, we
furtherevaluatedwhetherornotxanthohumoldirectlybinds
to the platelet αIIbβ3 integrin, leading to interruption of
platelet aggregation. In this study, the relative intensity of
the ﬂuorescence of 2μg/mL FITC-triﬂavin bound direct-
ly to 1μg/mL collagen-activated platelets was 26.8 ± 0.5
(n = 5) (Figure 2(a) (A)), and it was markedly reduced in
the presence of 5mM EDTA(negative control,9.7 ± 0.5,P<
0.001;n = 5)(Figure 2(a)(B)).Xanthohumol(1.5and3μM)
did not signiﬁcantly aﬀect FITC-triﬂavin binding to the
αIIbβ3 integrin in platelet suspensions (1.5μM, 26.9 ± 0.6;
3μM, 28.0 ±0.7; n = 5) (Figure 2(a) (C, D)), indicating that
the inhibitory eﬀect of xanthohumol on platelet aggregation
does not involve binding to the platelet αIIbβ3 integrin. Fur-
thermore, resting platelets produced relatively low amounts
of thromboxane B2 compared to agonist-activated platelets
(i.e., collagen). At 3μM, xanthohumol inhibited both
1μg/mL collagen- and 60μM AA-stimulated thromboxane
B2 formation by approximately 56% and 10%, respective-
ly, but it was not signiﬁcantly aﬀected by 0.05U/mL
thrombin stimulation (Figure 2(b)). PLC hydrolyzes phos-
phatidylinositol 4,5-bisphosphate (PIP2) to generate two
secondary messengers: inositol 1,4,5-trisphosphate (IP3)a n d
diacylglycerol (DAG) [14]. DAG activates PKC, which then
phosphorylates p47 proteins (p47). Treatment with 1.5
and 3μM xanthohumol concentration dependently abol-
ished the phosphorylation of PLCγ2 stimulated by collagen
(Figure 2(c)).
3.3. Xanthohumol on PKC Activation. Stimulation of plate-
lets with a number of diﬀerent agonists(such as colla-
gen)or PDBu, an activator of PKC[15], markedly induces
PKC activation (p47phosphorylation). In the present
study, when1μg/mL collagen (Figure 3(a))or150nM PDBu4 Evidence-Based Complementary and Alternative Medicine
A
T
P
 
r
e
l
e
a
s
e
Collagen
DMSO
XN
1.5
3
Thrombin
DMSO
XN
3 10
DMSO
XN
3 10
AA
DMSO
XN
3 10
U46619
Δ
T
(
%
)
(min)
(a)
02468 1 0
0
20
40
60
80
100
I
n
h
i
b
i
t
i
o
n
 
(
%
)
Concentration (μM)
(b)
0
10
20
30
40
50
60
##
##
Collagen
XN DMSO 1.5 3
∗∗
−
−
+++
[
C
a
2
+
]
i
(
n
M
)
(c)
Figure 1: Eﬀects of xanthohumol (XN) on the inhibition of platelet aggregation and relative [Ca2+]i mobilization in activated platelets.
Washed platelets (3.6 × 108 cells/mL) were preincubated with 1.5∼10μM XN or a solvent control (0.5% DMSO), followed by the addition
of 1μg/mL collagen ( ), 1μM U46619 ( ), 60μM arachidonic acid (AA;  ), or 0.05IU/mL thrombin (♦) to trigger ((a)-(b)) platelet
aggregation and an ATP-release reaction ((a), top-left corner) or (c) relative [Ca2+]i mobilization. Proﬁles (a) are representative examples of
six similar experiments. Data ((b) and (c)) are presented as the means ± S.E.M. ((b), n = 6; (c), n = 3); ∗∗P<0.01, compared to the resting
group; ##P<0.01, compared to the control (DMSO) group.
(Figure 3(b)) was added to human platelets, a protein with
an apparent molecular weight of 47kDa (p47) was predom-
inately phosphorylated compared to resting platelets. Xan-
thohumol (1.5 and 3μM) concentration dependently inhib-
ited p47 phosphorylation stimulated by collagen but not by
PDBu(Figures3(a)and3(b)).As shown in the Figure 3(c),
xanthohumol did not signiﬁcantly aﬀect PDBu-(150nM)
induced platelet aggregation. These results indicate that
xanthohumol abolished PKC activation through inhibiting
PLCγ2 phosphorylation.
3.4. Xanthohumol Attenuates MAPKs and Akt Activation. To
further investigate the inhibitory mechanisms of xanthohu-
mol in platelet activation, we detected several signaling mol-
ecules such as MAPKs(i.e., p38 MAPK, ERK1/2, andEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of xanthohumol (XN) on FITC-triﬂavin binding to the αIIbβ3 integrin, thromboxane B2 formation, and phospholipase Cγ2
(PLCγ2) phosphorylation in activated platelets. (a) The solid line represents the ﬂuorescence proﬁles of (A) 2μg/mL FITC-triﬂavin in the
absence of XN as a positive control, (B) in the presence of 5mM EDTA as a negative control, or in the presence of (C) 1.5 and (D) 3μM
XN, followed by the addition of 2μg/mL FITC-triﬂavin. For other experiments, washed platelets were preincubated with 3μMX No r0 . 5 %
DMSO, followed by the addition of 1μg/mL collagen, 60μM arachidonic acid (AA), or 0.05U/mL thrombin to trigger platelet activation.
Cells were collected, and subcellular extracts were analyzed for (b) thromboxane B2 formation, and (c) PLCγ2 phosphorylation as described
in Section 2. Proﬁles (a) are representative examples of ﬁve similar experiments. Data ((b) and (c)) are presented as the means ± S.E.M. ((b),
n = 4; (c), n = 6). ∗∗P<0.01 and ∗∗∗P<0.001, compared to the resting group; #P<0.05, ##P<0.01 and ###P<0.001, compared to the
control (DMSO) group.
JNK1/2) and Akt. Xanthohumol (3μM) attenuated the
phosphorylation of p38 MAPK (Figure 4(a)), ERK1/2
(Figure 4(b)), JNK1 (Figure 4(c)), and Akt (Figure 4(d))
stimulated by 1μg/mL collagen.
3.5. Eﬀects of Xanthohumol on Cyclic Nucleotides, and Nitrate
and Hydroxyl Radical (OH•) Formation in Collagen-Activated
Platelets. As shown in Figures 5(a) and 5(b), ODQ (20μM)
and SQ22536 (100μM), inhibitors of guanylate cyclase
and adenylate cyclase, obviously reversed nitroglycerin-
(NTG; 10μM) and PGE1-(10μM) mediated inhibition
of platelet aggregation stimulated by collagen, respec-
tively; however, neither inhibitor responded to xanthohu-
mol (3μM)-mediated inhibition of platelet aggregation.
Xanthohumol (3μM) did not signiﬁcantly increase cyclic
AMP or cyclic GMP levels in human platelets(data not
shown). Furthermore, NO was quantiﬁed using a sensitive6 Evidence-Based Complementary and Alternative Medicine
0
0.5
1
1.5
2
p-p47
Collagen
XN DMSO 1.5 3
p
4
7
 
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
 
(
f
o
l
d
s
/
b
a
s
a
l
)
##
#
∗∗∗
−
−
+++
α-tubulin
(a)
p
4
7
 
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
 
(
f
o
l
d
s
/
b
a
s
a
l
)
0
0.5
1
1.5
2
PDBu
XN
∗∗
p-p47
α-tubulin
DMSO 1.5 3
−
−
+++
(b)
DMSO
XN
1.5 3
PDBu
Δ
T
(
%
)
(min)
DMSO
XN
1.5
Δ
T
(
%
)
(m
3
(c)
Figure 3: Inhibitory activity of xanthohumol (XN) on protein kinase C (PKC) activation in activated platelets. Washed platelets were
preincubated with 1.5 and 3μM XN or 0.5% DMSO, followed by the addition of 1μg/mL collagen or 150nM PDBu to trigger ((a) and
(b)) PKC activation or (c) platelet aggregation. Cells were collected, and subcellular extracts were analyzed for ((a) and (b)) phosphorylation
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∗∗∗P<0.001comparedtotherestinggroup; #P<0.05and ##P<0.01comparedtothecontrol(DMSO)group.Proﬁles(c)arerepresentative
examples of three similar experiments.
and speciﬁc ozone redox-chemiluminescence detector as
shown in Figure 5(c). The production of nitrate markedly
increased with 10μM NTG activation compared to the
resting group, whereas xanthohumol (1.5 and 3μM)did
not reach statistical signiﬁcance. On the other hand, a
typical ESR signal of hydroxyl radical(OH•) formation was
triggered in collagen-activated platelets comparedtoresting
platelets(Figure 5(d)(A,B)),and treatment with xanthohu-
mol (1.5and3μM) obviously reduced hydroxyl radical for-
mation stimulated by collagen (Figure 5(d) (C, D)).
4. Discussion
This study reveals for the ﬁrst time that xanthohumol, be-
sides its well-known anticancer properties,also possesses po-
tent antiplatelet activity. Xanthohumol is the major prenyl-
ﬂavonoid of hops(0.1% ∼ 1% on a dry weight basis)[16],
andxanthohumolanditsrelatedprenylﬂavonoidsareknown
to be contained in beer as a dietary source. The average per-
son in the USA consumed 225mL/day of beer in 2001 [16].
Therefore, the daily intake of total prenylﬂavonoids would
be approximately 0.14mg. Studies of the pharmacokinetics
revealed that the maximal plasma concentration was ap-
proximately 180nM after 4h of oral administration of
50mg/kg xanthohumol in rats [16]. Indeed, dietary intake of
prenylﬂavonoids (xanthohumol) through normal beer con-
sumption would not be suﬃcient to achieve plasma concen-
trations that could inhibit platelet activation. Ideally, athero-
thrombotic prevention is achieved by long-term exposure to
nontoxic agents, preferably as part of certain food products
or nutritional supplements. Xanthohumol showed no toxic-
itytolivercellsnordiditinhibitmitochondrialrespirationor
uncouple oxidative phosphorylation in isolated rat liver mi-
tochondria at 10μM[ 17]. Therefore, xanthohumol is con-
sidered to be the best phytochemical isolated from hops to
investigate antiplatelet functions.
Gerhauseretal.[4]reportedthatxanthohumolcanbean
eﬀective anti-inﬂammatory agent by inhibiting endogenous
prostaglandin synthesis through inhibition of cyclooxyge-
nases (constitutive COX-1 and inducible COX-2). In theEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Xanthohumol (XN) on p38 MAPK, ERK1/2, JNK1/2, and Akt phosphorylation in collagen-activated platelets. Washed platelets
(1.2 × 109 cells/mL) were preincubated with 1.5 and 3μM XN or 0.5% DMSO, followed by the addition of 1μg/mL collagen to trigger
platelet activation. Cells were collected, and subcellular extracts were analyzed for (a) p38 MAPK, (b) ERK1/2, (c) JNK1/2, and (d) Akt
phosphorylation. Data are presented as the means ± S.E.M. (n = 4). ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001, compared to the resting
group; #P<0.05 and ##P<0.01, compared to the control (DMSO) group.
present study, collagen-induced thromboxane B2 formation,
astablemetaboliteofthromboxaneA2,wasalsomarkedlyin-
hibited by xanthohumol. In platelets, AA is released fromcell
membranes and converted to thromboxane A2.T h r o m b o x -
ane A2 is important for collagen- and AA-induced platelet
aggregation, which may explain the more-potent activity
of xanthohumol in inhibiting collagen- and AA-induced
platelet aggregation than other agonists (i.e., thrombin).
Stimulation of platelets by agonists (i.e., collagen) causes
marked alterations in phospholipid metabolism. Activation
of PLC results in the production of IP3 and DAG, which
activates PKC, inducing protein phosphorylation (p47) [18].8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Regulation of platelet aggregation, nitrate formation, and hydroxyl radical (OH•) formation by xanthohumol (XN). ((a) and (b))
Washed platelets (3.6 × 108 cells/mL) were preincubated with 10μM prostaglandin E1 (PGE1), 10μM nitroglycerin (NTG), or 3μMX Ni n
the absence or presence of 20μM ODQ or 100μM SQ22536, followed by the addition of 1μg/mL collagen to trigger platelet aggregation.
Proﬁles are representative examples of three similar experiments. On the other hand, (c) washed platelets (109 cells/mL) were incubated with
10μM nitroglycerin (NTG), and 1.5 and 3μM XN. Cells were then collected, and subcellular extracts were analyzed for nitrate formation as
described in Section 2. Data are presented as the means ± S.E.M. (n = 4). ∗∗∗P<0.001, compared to the resting group. (d) For the electron
spinresonance(ESR)study,washedplatelets(3.6 ×108 cells/mL)wereincubatedwith(A)Tyrode’ssolutiononly(restinggroup),orplatelets
were preincubated with (B) the control (0.5% DMSO), (C) 1.5 μM, or (D) 3μM XN followed by the addition of 1μg/mL collagen to trigger
hydroxyl radical formation. Spectra are representative examples of three similar experiments. An asterisk (∗) indicates the formation of
hydroxyl radicals.
PKC activation represents a strategy adopted by cells to allow
selected responses to speciﬁc activating signals in distinct
cellular compartments [19]. PLCγ2 is involved in collagen-
dependent signaling in platelets [20]. In this study, both
PLCγ2 phosphorylation and PKC activation were inhibited
by xanthohumol, suggesting that xanthohumol-mediated
antiplatelet activity is involved in inhibiting the PLCγ2-PKC
signal pathway.
MAPKs consist of three major subgroups. ERKs (p44
ERK1andp42ERK2)areinvolvedinproliferation,adhesion,
and cell progression [21]. p38 MAPK and JNKs, which
include the 46-kDa JNK1 and 55-kDa JNK2 isoforms, are
involved in apoptosis [21]. ERK2, JNK1, and p38 MAPK
were all identiﬁed in platelets [21]. The physiopathological
roles of JNK1/2 and ERK1/2 are unclear in platelets, but
they were suggested to be suppressors of αIIbβ3 integrin
activation or negative regulators of platelet activation [22].
On the other hand, p38 MAPK provides a crucial signal for
aggregation caused by collagen. We found that SB203580,
an inhibitor of p38MAPK, markedly inhibited 1μg/mL
collagen-induced platelet aggregation (data not shown).
Among the numerous downstream targets of p38 MAPK,
the most physiologically relevant one in platelets is cytosolic
phospholipase A2 (cPLA2) which catalyzes AA release to
produce thromboxane A2 [23]; thus, MAPKs (especially p38
M A P K )a p p e a rt oh a v eap i v o t a lr o l ei np l a t e l e ta c t i v a t i o n .
On the other hand, knockout of Akt in mice resulted in
defects of platelet activation stimulated by agonists [24, 25].
Akt functions as one of several downstream eﬀectors of
PI3-kinase [26]. Recently, we found that both p38 MAPK
and PI3-kinase/Akt act in mutual activation as upstream
regulators of PKC in activated platelets [27]. Therefore, Akt
phosphorylation seems to play a crucial role in platelet
activation. On the other hand, activation of human platelets
is inhibited by two intracellular pathways regulated by
either cyclic AMP or cyclic GMP. The importance of cyclic
nucleotides in modulating platelet reactivity is well estab-
lished [28]. In addition to inhibiting most platelet responses,
elevated levels of cyclic nucleotides decrease intracellular
Ca2+ concentrations by the uptake of Ca2+ into the dense
tubular system (DTS) which negatively aﬀects the actions
of PLC and PKC [28]. Therefore, cyclic AMP and cyclic
GMP act synergistically to inhibit platelet aggregation. In
addition, platelets produce NO in smaller amounts than doEvidence-Based Complementary and Alternative Medicine 9
endothelial cells [29]. Most cellular actions of NO occur
via stimulation of intracellular guanylate cyclase, leading
to increases in cyclic GMP. In this study, we found that
xanthohumol-mediated antiplatelet activity, at least in part,
was not regulated by NO or cyclic nucleotides.
Reactive oxygen species (ROS; hydrogen peroxide, hy-
droxyl radicals, etc.) derived from platelet activation might
amplify platelet reactivity during in vivo thrombus forma-
tion. Free radical species act as secondary messengers that
increase cytosolic Ca2+ during the initial phase of platelet ac-
tivation processes, and PKC is involved in receptor-mediated
free radical production in platelets [12]. It is also evident
that some of the hydrogen peroxide produced by platelets is
converted into hydroxyl radicals, as platelet aggregation
can be inhibited by hydroxyl radical scavengers [12]. ROS-
scavenging activity of xanthohumol was studied by Ger-
hauser et al. [4] who found that xanthohumol was about
9-fold more potent than trolox at a concentration of 1μM
at scavenging hydroxyl and peroxyl radicals as analyzed by
an indirect method of an oxygen radical antioxidant capacity
(ORAC) assay. In the present study, a similar result, obtained
from the ESR study in which xanthohumol scavenges OH•
formation, provided direct evidence of its free radical-scav-
enging activity.
Data generated in this investigation suggest that xantho-
humol has a novel role in antiplatelet activation and can
likely be used as a nutritional or dietary supplement as a pro-
phylactic. Generally, a nutritional or dietary supplement is
required to demonstrate a prophylactic eﬀect in humans
which may depend on individual characteristics; hence it
may be impossible to delineate a selection of doses for time-
course treatment, since it may vary from one individual to
another. Nevertheless, this study provides new insights de-
scribing the mechanisms of xanthohumol at the studied
doses in blocking speciﬁc signaling events during agonist-
induced platelet activation.
In conclusion, the most important ﬁndings of this study
demonstratefortheﬁrsttimethattheverypotentantiplatelet
activity of xanthohumol may initially inhibit the PI3-kinas-
e/Akt, p38 MAPK and PLCγ2-PKC cascades, followed by in-
hibitionofthromboxaneA2 formation,therebyleadingtoin-
hibition of [Ca2+]i and ﬁnally inhibition of platelet aggrega-
tion.Plateletaggregationplaysimportantpathophysiological
roles in a variety of thromboembolic disorders. Therefore,
the novel role of xanthohumol in antiplatelet activation may
represent high therapeutic potential for treating or prevent-
ingsuchdiseases,inadditiontoitoriginallybeingconsidered
as a chemopreventive agent.
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